Breast Cancer Drugs Market Size and Forecast 2024-2033| F. Hoffmann-La Roche Ltd., Novartis AG, AstraZeneca PLC, Eli Lilly and Company Inc., Biocon Limited

Doctor is working with mammography X-ray scanner in hospital

Overview and Scope

Breast cancer drugs refer to anti-cancer medications that can be taken orally or intravenously (injected into a vein). The majority of the body’s cancer cells are reached by the medications via the bloodstream. Chemotherapy may occasionally be administered directly into this region if cancer has spread to the spinal fluid, which surrounds and protects the brain and spinal cord (called intrathecal chemotherapy).

Sizing and Forecast

The breast cancer drugs market size has grown strongly in recent years. It will grow from $36.42 billion in 2023 to $39.63 billion in 2024 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to increasing incidence of breast cancer, advancements in research and development, screening and early detection, evolving treatment guidelines, healthcare infrastructure development.

The breast cancer drugs market size is expected to see strong growth in the next few years. It will grow to $54.7 billion in 2028 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to rising aging population, emerging markets, supportive policies and regulations, patient advocacy and awareness. Major trends in the forecast period include personalized medicine, targeted therapies and immunotherapies, clinical trials and drug pipeline, combination therapies, biomarker-driven treatments, telemedicine and remote monitoring.

To access more details regarding this report, visit the link:

https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report

Segmentation & Regional Insights

The breast cancer drugs market covered in this report is segmented –

1) By Type: Metastatic Breast Cancer, Triple Negative Breast Cancer, Others (Ductal Carcinoma Insitu, Invasive Ductal Carcinoma, Inflammatory Breast Cancer, Breast Cancer During Pregnancy, Others)

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Other Distribution Channels

3) By End User: Amubulatory, Hospitals, Clinics, Other End-Users

Sub-Segments

By Drug Type: HER2 Inhibitors, Mitotic Inhibitors, Anti-Metabolites, Aromatase Inhibitors, Hormonal Receptor

North America was the largest region in the breast cancer drugs market in 2023. The Middle East is expected to be the fastest-growing region in the breast cancer drugs market during the forecast period. The regions covered in the breast cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2566&type=smp

Major Driver Impacting Market Growth

The increasing prevalence of breast cancer is driving the breast cancer drug market. Breast cancer is the most common type of cancer among women and affects around 2.1 million women each year. According to the American Cancer Society, there were an estimated 284,200 new breast cancer cases and an estimated 44,130 people died of breast cancer in 2021. The factors responsible for breast cancer include the heredity, age, and lifestyle of a person, and are more common in developed countries. As the number of people diagnosed with breast cancer rises, the demand for breast cancer drugs increases, thereby driving the growth of the breast cancer drugs market.

Key Industry Players

Major companies operating in the breast cancer drugs market include F. Hoffmann-La Roche Ltd., Novartis AG, AstraZeneca PLC, Eli Lilly and Company Inc., Biocon Limited, Merck & Co. Inc., Genzyme Corporation, Johnson & Johnson, MacroGenics Inc., Celldex Therapeutics Inc., Onyx Pharmaceuticals Inc., BioNumerik Pharmaceuticals Inc., AbbVie Inc., Pfizer Inc., OncoGenex Pharmaceuticals Inc., Astellas Pharma Inc., Bristol-Myers Squibb Company, Bayer AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Abbott Laboratories, Apthera Inc., Oncothyreon Inc., BiPar Sciences Inc., Puma Biotechnology Inc., Sanofi S.A., Genentech Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Eisai Co. Ltd., Mylan N.V., Dr. Reddy’s Laboratories Ltd., Accord Healthcare Limited, Alkem Laboratories Limited, Natco Pharma Limited, Fresenius Kabi AG, Lupin Limited, Glenmark Pharmaceuticals Limited

The breast cancer drugs market report table of contents includes:

1. Executive Summary

2. Breast Cancer Drugs Market Characteristics

3. Breast Cancer Drugs Market Trends And Strategies

4. Breast Cancer Drugs Market – Macro Economic Scenario

5. Global Breast Cancer Drugs Market Size and Growth

26. South America Breast Cancer Drugs Market

27. Brazil Breast Cancer Drugs Market

28. Middle East Breast Cancer Drugs Market

29. Africa Breast Cancer Drugs Market

30. Breast Cancer Drugs Market Competitive Landscape And Company Profiles

Top Major Players: